I did not foresee the China mini-crisis. But I watched with fascination. Because I had little cash in my account, on August 12 I raised cash by selling my Cantel Medical (CMN) stock, all of it. Cantel is a great company making infection control devices. When I bought it in December of 2009 for $19.58 per share, after hearing about […]
By Jason Napodano, CFAThe IBB is down 16% from its highs. That’s probably not the bottom, but it does still represent a nice buying opportunity for long-term investors.
I look for stocks with at least 12 months cash, clean capital structures, credible management, near-term catalysts, and charismatic technology.In my article I highlight some names that I either currently own or am […]
Going down the list of stocks in the IBB, my next stop was United Therapeutics (UTHR). I spent about a day doing research and wrote up my conclusions for Seeking Alpha:United Therapeutics Appears UndervaluedI concluded I did not want to buy UTHR at the present time. Buying it a year ago would have been smart, but then a lot of […]
Related WINWindstream’s REIT Spin-Out & Reverse Stock-Split – Now What?Windstream Awarded Federal Government GSA Contract for Green Buildings Initiative7 Top Dividend Sector Dogs Fetch 24% To 50% April Upsides(Seeking Alpha)Related Windstream’s REIT Spin-Out & Reverse Stock-Split – Now What?Windstream Will No Longer Pay The S&P 500’s Highest Yield: What Investors Need To KnowWindstream wraps tax-free spinoff of CS&L REIT(Seeking Alpha)Joel […]
Related BIIBStifel Downgrades Biogen Amid Concerns Of Lack Of Upcoming Data, OvervaluationBenzinga’s Top #PreMarket LosersIs Biogen Stock Worth Considering Right Now?(Seeking Alpha)Related GILDGilead Shares Tumble On Drug Warning; Baird Says BuyBenzinga’s Top #PreMarket LosersSeeking Alpha’s Biotech Weekly: Biogen’s Plaque Attack, Amgen Or Gilead?, And More(Seeking Alpha)A number of biotech stocks were soaring in Friday’s premarket following positive news.Biogen Idec Inc […]
SummaryFull review of market performance in 2014 for the Dow Jones, NASDAQ, and S&P 500.
The best opportunities and weaknesses to be aware of coming into 2015.
What strategists and banks are forecasting for 2015 stock market.
2015 stock market forecast for the short, mid, and long term based on state of the art predictive algorithms.
How 2014 performed with accordance to 2013 predictionsDow […]
SummaryDoing due diligence on a small portion of the mosaic theory related to Inovio and other biotechs led me to doing a small initial study on RedChip.
While RedChip has Inovio listed prominently in multiple areas on its website and has recently Tweeted about it, Inovio is not a client and has never paid RedChip.
Biotech and healthcare stocks listed as RedChip […]
SummaryIntel is planning to apply Big Data into medicine by pairing smartwatches with its analytics software.
Intel and the Michael J. Fox Foundation have joined hands for conducting a study on Parkinson’s disease.
In our original article, we said that Intel has tremendous opportunities in the IoT, although we didn’t anticipate that Intel would go into medicine.
The recent news confirms our view […]
SummaryWe argue that the talk of a stock market bubble relies on too much focus from the depths of 2009 to today.
It is important to examine long time periods of over ten years.
When examining time periods of ten years or more, we find the US stock market has provided investors poor returns over the last ten years meaning no bubble.
SummarySuddenly nearly everybody is bullish at historic highs. Where were they at the post-IPO lows?
Facebook is priced for beyond perfection at 94 times earnings and 24 times sales.
Original VC Peter Thiel cashes out his remaining 494,950 shares on July 29, signaling a smart money top.
There have been so many ridiculously bullish articles on Facebook (NASDAQ:FB) lately that I don’t even […]